



LMA International NV

22 February 2008

Announcement to the Singapore Exchange

LMA TO APPEAL DECISION OF EUROPEAN PATENT OFFICE TO REVOKE PATENT

Mainboard-listed LMA International NV (“LMA” or the “Company”), the global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management, wishes to provide an update on the ongoing legal proceedings against Ambu A/S in Europe.

On 20 February 2008, the Opposition Division of the European Patent Office (“EPO”) revoked the Company’s European Distal – Rib Patent number EP 1119386. The basis for the EPO’s decision can be removed by the Company making a simple amendment to the wording of one of the claims in its patent. LMA will effect this amendment when it files its appeal against the decision.

EP 1119386 is the subject of LMA’s patent infringement proceedings against Ambu A/S (“Ambu”) and its subsidiaries in Germany, The Netherlands and France.

As Ambu’s objection to EP 1119386 in the European Patent Office does not apply to LMA’s German Utility model, the Company believes the EPO’s decision will not affect its existing damages claim for Ambu’s infringement of that utility model in Germany. However, the Company expects the Dutch and French actions to be suspended pending the resolution of its appeal of the EPO’s decision.

The EPO decision does not affect the Company’s patent infringement proceedings against Ambu in the United States.

Mr John Lim, Executive Deputy Chairman, said, “While we are disappointed with the EPO’s decision, we remain convinced of the validity of our patent and will be appealing the decision.”

LMA International NV

Osprey House, Old Street, St. Helier, Jersey JE2 3RG, Channel Islands

ENDS

NOTES:

LMA International NV

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Germany and San Diego, California. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.

LMA™ Airways

For over 20 years, The Laryngeal Mask Company Limited has been making advances in airway design and technology which have impacted directly on patient safety and comfort. British anaesthetist Dr Archie Brain designed the first LMA™ airway in 1988. Since then, LMA™ airways have been used over 200 million times around the world and are supported by over 2,500 published references. The LMA™ airway has become the most well-known and respected supraglottic airway device worldwide, with a full range of products designed for specialist clinical needs including routine anaesthesia, PPV, ENT surgery, the difficult airway and emergency situations.

LMA Patent Portfolio

LMA has an extensive patent portfolio that protects the key products in the LMA™ range, as well as new products currently under development. The Company's portfolio comprises an estimated 335 granted and pending patents worldwide, the majority of which have a significant unexpired term. Of the Company's granted patents, the earliest expiry date is 2008, and the latest is around 2025.